To test their efficacy in HER2-positive breast cancers, three different cell lines (AU565, SKBR3, and HCC-1954) were treated with 1E5, and effects on cell proliferation were measured by tetrazolium salt reduction (MTS) and trypan blue exclusion assays. Here, ERBB2 is linked to breast cancer.